STOCKHOLM, June 13, 2025 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) announced today that the interim safety review of the clinical Phase 2a study EXIST showed exidavnemab to be safe and well-tolerated, whereby the second dose cohorts will now be initiated. The EXIST...
Read More Details
Finally We wish PressBee provided you with enough information of ( BioArctic to initiate next cohorts in exidavnemab Phase 2a study after positive safety review )
Also on site :
- ‘90s Country Star, 60, Shows off Slimmed Down Look at Intimate Show: ‘Beautiful'
- Star-Studded Tribute to Brian Wilson With Tom Hanks, Bruce Springsteen, Michael McDonald, Elton John and More Re-Airing on CBS
- 2 HGTV Stars Turn Heads In Cheeky Bikinis